A detailed review of the overall landscape of companies offering contract services for the manufacturing of HPAPIs and cytotoxic drugs

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment

Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030”,

Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications.

Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios

Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.””

The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis

A detailed assessment of the current market landscape of companies offering patient recruitment and retention service

A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden

resently, close to 140 companies claim to be actively engaged in offering patient recruitment / retention services to the pharmaceutical and medical devices industries, employing a variety of outreach methods and solutions

Roots Analysis is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Marker, 2019-2030.”